Author: slightbourne@noblecapitalmarkets.com

MAIA Biotechnology (MAIA) – Roche Forms Supply Agreement For THIO Combination Studies

Posted on by slightbourne@noblecapitalmarkets.com


Friday, June 20, 2025

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

MAIA Makes Its Third Supply Agreement. MAIA announced that it has entered a supply agreement with Genentech/Roche to test THIO (ateganosine) in combination with Tecentriq (atezolizumab, Roche’s PD-L1 checkpoint inhibitor) for the treatment of several hard-to-treat cancers. MAIA now has supply agreements to test THIO in combination with checkpoint inhibitors from three global pharmaceutical companies, which we see as an indicator of interest for future partnerships.

PD-1 or PD-1L? That Is The Question. Checkpoint inhibitors block the interaction of the surface proteins PD-1 (programmed death receptor-1) with PD-1L (the programed death receptor-1 ligand). When the PD-1 receptor binds to the PD-1L ligand, it inhibits the immune response. Checkpoint inhibitors are monoclonal antibody drugs against PD-1 or PD-L1 that block this interaction, allowing cancer cells to be recognized by a patient’s immune system and killed.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Euroseas (ESEA) – Strong Start to 2025

Posted on by slightbourne@noblecapitalmarkets.com


Friday, June 20, 2025

Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 140 years. Euroseas trades on the NASDAQ Capital Market under the ticker ESEA. Euroseas operates in the container shipping market. Euroseas’ operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

First quarter 2025 financial results. Euroseas Ltd. reported adjusted EBITDA and earnings per share (EPS) of $37.1 million and $3.76, respectively, compared to $24.6 million and $2.66 during the prior year period. Revenue increased due to a higher average number of vessels compared to the same period last year, while operating expenses declined. We had projected adjusted EBITDA and EPS of $34.7 million and $3.35, respectively. Relative to our estimates, revenues were higher, based on an average daily time charter equivalent rate of $27,806, versus our estimate of $26,221, while operating expenses were lower. Vessel operating expenses totaled $12.3 million compared to our estimate of $13.3 million.

Market outlook. The containership sector may face some challenges, including the potential for transit to resume through the Suez Canal, weaker economic conditions due to fluid trade policies, and a high industry order book, which could increase the supply of vessels. However, the company’s strong charter coverage through 2026 could insulate it from the potential for lower rates. Moreover, the feeder and intermediate segments of the market have relatively low order books, and demand for vessels remains strong.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

U.S. Considers Ending Chip Waivers to China, Sending Semiconductor Stocks Lower

Posted on by slightbourne@noblecapitalmarkets.com

Semiconductor stocks stumbled Friday after reports surfaced that the U.S. government is considering revoking waivers that currently allow major global chipmakers to use American technology in their Chinese operations.

According to The Wall Street Journal, Commerce Department official Jeffrey Kessler informed executives from Samsung Electronics, SK Hynix, and Taiwan Semiconductor Manufacturing Company (TSMC) earlier this week that the Biden administration is reviewing whether to terminate these exemptions. The waivers had enabled companies to export U.S. chipmaking tools and software to facilities in China, despite existing export controls.

The news triggered a wave of selling across the semiconductor sector. The VanEck Semiconductor ETF (SMH) dropped around 1%, while individual stocks including Nvidia, Qualcomm, and Marvell Technology fell roughly 1%. TSMC shares declined more than 2% as investors reacted to the potential disruption to its China-based operations.

The Commerce Department’s move signals a possible escalation in the ongoing tech tensions between Washington and Beijing. Although the two nations recently agreed on the framework of a second trade deal during meetings in London, the Biden administration has continued to tighten restrictions on advanced chip technology exports, citing national security concerns.

“These waivers were a key lifeline for chipmakers operating in China,” said Adam Kinley, an analyst at EastWest Securities. “If revoked, companies like TSMC and Samsung could face operational hurdles, reallocation costs, and potentially a sharp drop in revenue tied to China-based production.”

The semiconductor industry has already been navigating growing restrictions. In 2022 and 2023, the U.S. introduced sweeping controls limiting China’s access to advanced AI chips and tools required for high-end semiconductor fabrication. The latest efforts to close loopholes reflect Washington’s concern that Beijing could exploit foreign chip factories operating inside China to circumvent those controls.

The impact of these export curbs is already being felt. Nvidia, a leading AI chipmaker, disclosed last month that U.S. government restrictions on its China-bound H20 chips contributed to an estimated $8 billion hit in sales. CEO Jensen Huang described the China market—once worth $50 billion to U.S. chip companies—as “effectively closed.”

The potential rollback of waivers could further strain U.S.-China trade relations, particularly as China has denounced these restrictions as discriminatory. While the current policy discussions are ongoing and no final decision has been made, the possibility of more sweeping limits has introduced fresh volatility into the sector.

Investors and chipmakers alike will be watching closely for any formal announcements in the coming weeks. A reversal of the waivers would force affected companies to reevaluate supply chains, consider shifting manufacturing operations out of China, and potentially delay production schedules.

In the near term, analysts expect heightened market sensitivity to any government signals or diplomatic developments related to U.S.-China tech policy. As Washington balances national security priorities with global economic interests, the semiconductor industry finds itself once again at the center of geopolitical risk.

GENIUS Act Passes Senate: What It Means for Crypto and Stablecoin Investors

Posted on by slightbourne@noblecapitalmarkets.com

In a historic move for the crypto industry, the U.S. Senate has passed the GENIUS Act—short for Guiding and Establishing National Innovation for US Stablecoins—laying the foundation for the first federal framework governing stablecoins. Though the bill still awaits approval from the House of Representatives and President Trump’s signature, its Senate passage marks a seismic shift in crypto policy that could reshape the digital asset landscape.

Stablecoins, digital tokens typically pegged to the U.S. dollar, are widely used for trading, payments, and preserving value in volatile markets. The GENIUS Act aims to bring oversight and legitimacy to this rapidly growing segment by requiring issuers to maintain full reserves in cash or U.S. Treasury assets, undergo routine audits, and publicly disclose their reserve compositions monthly.

The legislation has already catalyzed a dramatic response. According to CoinDesk, the total market capitalization of stablecoins surged to a record $251.7 billion, reflecting a 22% year-to-date increase. Industry leaders, including Circle (CRCL)—the largest U.S. stablecoin issuer—have hailed the bill as a breakthrough. Circle’s stock has soared 400% since going public in early June, signaling investor confidence in the sector’s regulated future.

“This bill gives us the right foundation,” said Dante Disparte, Circle’s Chief Strategy Officer. “Whether you’re a bank, a fintech, or a non-bank issuer, you now have a common regulatory floor.”

One of the most consequential elements of the GENIUS Act is its two-tiered regulatory approach: large issuers with over $10 billion in assets will fall under federal oversight, led by the Federal Reserve and Office of the Comptroller of the Currency (OCC), while smaller issuers will be supervised by state regulators. Additionally, the act prohibits stablecoins from paying interest, a provision meant to draw a clear line between digital currencies and traditional savings products.

The bill also restricts members of Congress and their families from profiting off stablecoin ventures—though notably excludes President Trump and his family, sparking some partisan criticism. Trump’s growing involvement in the sector, including the launch of USD1 stablecoin by his crypto firm World Liberty Financial, has raised eyebrows and energized Republican support.

Big banks and corporations are now eyeing stablecoin issuance. Bank of America has confirmed it is exploring options, and Amazon and Walmart are reportedly assessing opportunities, though both companies remain cautious. The potential for new entrants to bypass traditional payment rails like Visa and Mastercard could be disruptive—and lucrative.

Despite concerns over investor runs and tech monopolies, the GENIUS Act includes strict consumer protection clauses, criminal penalties for noncompliance, and Treasury approval for tech firms wishing to issue stablecoins. Treasury Secretary Scott Bessent projects the U.S. stablecoin market could exceed $2 trillion by 2028 if the bill becomes law.

As the House prepares to review the bill—possibly attaching it to broader crypto legislation—investors are bracing for what could be the most significant wave of adoption and innovation in crypto history. If passed in full, the GENIUS Act could signal not just regulation—but a rebranding of stablecoins from speculative tools to mainstream financial instruments.

Vince Holding Corp. (VNCE) – Mitigates Tariff Risks Much Faster Than Expected

Posted on by slightbourne@noblecapitalmarkets.com


Wednesday, June 18, 2025

500 5th Avenue 20th Floor New York, NY 10110 United States Sector(s): Consumer Cyclical Industry: Apparel Manufacturing Full Time Employees: 599 Key Executives Name Title Pay Exercised Year Born Mr. Jonathan CEO & Director 825.62k N/A 1958 Ms. Marie Fogel Senior VP and Chief Merchandising & Manufacturing Officer 633.19k N/A 1961 Mr. John Chief Financial Officer

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Solid Q1 results. the company reported Q1 revenue of $57.9 million and an adj. EBITDA loss of $3.0 million, both of which were better than our estimates of $56.0 million and a loss of $5.5 million, respectively. Notably, while revenue and adj. EBITDA are both modestly lower than the prior year period; we view the Q1 results favorably, given the company’s ability to manage the uncertain tariff outlook.

Tariff mitigation. The company highlighted that it has been taking steps to reduce its exposure to China, currently roughly 60% of its cost of goods sold. Notably, the company is sourcing from other countries and expects that China will be roughly 25% of its cost of goods by the end of 2025. The company has leadership located in the sourcing countries to ensure product quality. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

GoHealth (GOCO) – Noble Virtual Conference Highlights

Posted on by slightbourne@noblecapitalmarkets.com


Wednesday, June 18, 2025

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Highlights from Noble’s Emerging Growth Virtual Conference. Vijay Kotte, CEO, presented at Noble’s Virtual Equity conference June 4 & 5th. Mr. Kotte highlighted the company’s proprietary technology, consumer-centric Medicare policy platform, and gave an update on recent developments. A rebroadcast is available here.

Purpose-built technology. Mr. Kotte emphasized the company’s use of proprietary machine learning tools alongside licensed agents to tailor recommendations to each consumer’s needs. With Medicare beneficiaries typically choosing from 40–50 plans, this technology plays a key role in efficiently identifying the most suitable options.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Interest Rates on Hold Again as Fed Maintains Forecast for Two Cuts

Posted on by slightbourne@noblecapitalmarkets.com

The Federal Reserve held interest rates steady on Wednesday for the fourth consecutive meeting, keeping its benchmark rate in the range of 4.25% to 4.5% and reaffirming its forecast for two interest rate cuts before the end of 2025. The decision, which was supported unanimously by the Federal Open Market Committee, underscores the central bank’s cautious approach as it navigates a complex economic environment shaped by persistent inflation, slower growth expectations, and growing political pressure from the Trump administration.

Despite recent signs that inflation has eased modestly, the Fed raised its inflation outlook for the year. Officials now expect core PCE inflation, the central bank’s preferred metric, to end 2025 at 3.1%, up from a previous estimate of 2.8%. That adjustment reflects concerns that tariffs and other policy shifts under President Trump’s administration may continue to elevate prices and complicate the Fed’s path to achieving its 2% inflation target. At the same time, economic growth projections were lowered, with the Fed now anticipating annual GDP growth of 1.4%, down from 1.7%. The unemployment rate is also expected to climb slightly, from 4.4% to 4.5%, signaling a potential slowdown in the labor market as higher borrowing costs weigh on hiring and business investment.

The Fed’s statement noted that “uncertainty about the economic outlook has diminished, but remains elevated,” marking a shift in tone from earlier warnings that uncertainty was rising. While this change suggests that some risks may be stabilizing, policymakers remain sharply divided over the appropriate course of action. Eight officials project two rate cuts this year, while seven expect no cuts at all. Two members see a single cut, and two others anticipate as many as three. This internal split reflects the complexity of balancing inflation management with support for economic growth, particularly in a volatile political climate.

President Trump, who has been increasingly vocal in his criticism of Fed Chair Jerome Powell, once again expressed dissatisfaction with the central bank’s approach. Hours before the rate announcement, Trump took aim at Powell in front of reporters, joking that he might appoint himself to the Fed, claiming, “Maybe I should go to the Fed; I’d do a much better job.” He continued his push for lower rates by declaring that inflation is no longer a concern, stating, “We have no inflation, we have only success.” This political pressure has not gone unnoticed, but Powell and other Fed officials appear focused on maintaining their independence and credibility by anchoring decisions in economic data rather than political narratives.

Markets responded calmly to the announcement, with the S&P 500 rising 0.18% and the Dow Jones Industrial Average gaining 0.21%. Investors largely interpreted the Fed’s decision as a sign that rate cuts remain on the table, just not at the pace the White House may want. For now, the Fed continues to walk a careful line, seeking to bring inflation down without derailing a fragile recovery. With just months left in the year and political tensions rising, all eyes will remain on Powell and the FOMC as they weigh their next move.

Lilly Acquires Verve to Advance One-Time Gene Therapy for Heart Disease

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Lilly acquires Verve Therapeutics to develop one-time gene editing treatments for cardiovascular disease.
– Verve’s VERVE-102 targets the PCSK9 gene to lower cholesterol with a single dose.
– Deal strengthens Lilly’s position in cardiometabolic and genetic medicine sectors.

In a move set to transform the landscape of cardiovascular care, Eli Lilly and Company (NYSE: LLY) announced its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology firm focused on gene editing treatments for atherosclerotic cardiovascular disease (ASCVD). The transaction, valued at up to $1.3 billion, is aimed at accelerating the development of groundbreaking one-time treatments that could offer lifelong benefits to patients with high cardiovascular risk.

Verve’s lead program, VERVE-102, is a promising in vivo gene editing therapy targeting the PCSK9 gene—an established regulator of LDL cholesterol levels. Currently in a Phase 1b clinical trial, VERVE-102 has been granted Fast Track designation by the FDA and is designed for individuals with heterozygous familial hypercholesterolemia (HeFH) and certain forms of premature coronary artery disease. If successful, the treatment could eliminate the need for chronic medication by permanently modifying liver DNA to lower harmful cholesterol levels.

“This acquisition marks a bold step toward shifting cardiovascular care from lifelong therapy to one-time cures,” said Ruth Gimeno, Lilly’s Group VP of Diabetes and Metabolic Research and Development. “Combining Lilly’s global scale with Verve’s scientific innovation positions us to lead the next generation of cardiometabolic treatment.”

The purchase agreement includes an upfront cash payment of $10.50 per share—totaling approximately $1.0 billion—along with an additional contingent value right (CVR) worth up to $3.00 per share, tied to future clinical milestones. If all conditions are met, the total deal value could reach $1.3 billion. The acquisition represents a 113% premium over Verve’s 30-day average stock price prior to the announcement.

Founded just seven years ago, Verve has rapidly built a pipeline of one-time gene editing therapies aimed at the three core lipid-related drivers of ASCVD: low-density lipoproteins, triglycerides, and lipoprotein(a). In addition to VERVE-102, Verve is advancing VERVE-201 (targeting ANGPTL3 for refractory hypercholesterolemia) and VERVE-301 (targeting LPA for lipoprotein(a)-related risks).

“Joining Lilly is the natural next step in our mission to bring one-time gene editing treatments to people with cardiovascular disease,” said Dr. Sekar Kathiresan, co-founder and CEO of Verve. “Lilly’s world-class capabilities will significantly accelerate our clinical development and commercial reach.”

The deal is expected to close in Q3 2025, pending customary regulatory approvals and the successful tendering of Verve shares. Several major shareholders, including co-founders and investors affiliated with GV (formerly Google Ventures), have already agreed to tender approximately 17.8% of Verve’s outstanding stock.

For Lilly, this acquisition reinforces its strategic commitment to expanding in cardiometabolic and genetic medicine sectors—areas already central to its long-term growth strategy. As the race to develop durable, gene-based solutions for chronic illnesses intensifies, the Verve acquisition could position Lilly at the forefront of an entirely new therapeutic paradigm.

Ocugen (OCGN) – Stargardt Disease Program Moves To Phase 2/3 Trial

Posted on by slightbourne@noblecapitalmarkets.com


Tuesday, June 17, 2025

Ocugen, Inc. is a biotechnology company focused on developing and commercializing novel gene therapies, biologicals, and vaccines. The lead product in its gene therapy program, OCU400, is in Phase 1/2 clinical trials for retinitis pigmentosa.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

OCU410ST Cleared To Begin Confirmatory Trial. Ocugen announced that the FDA has approved its IND amendment to allow OCU410ST to begin its Phase 2/3 pivotal confirmatory trial. This will become the second Ocugen product to move into a Phase 2/3 confirmatory trial, and keeps the company on schedule to meet its goal of submitting three BLAs in the three years between 2026-28.

Brief Description of Stargardt Disease. Stargardt disease is a rare autosomal recessive disease caused by mutations in the ABCA4 gene in the retina. Progressive loss of photoreceptor cells in the retina typically starts at a young age, leading to blindness. Ocugen has received Orphan Drug designation and Rare Pediatric Disease Designation (RPDD) for diseases associated with ABCA4 diseases, including Stargardt, retinitis pigmentosa 19, and cone-rod dystrophy 3.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SKYX Platforms (SKYX) – Noble Virtual Conference Highlights

Posted on by slightbourne@noblecapitalmarkets.com


Tuesday, June 17, 2025

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Highlights from Noble’s Emerging Growth Virtual Conference. Lenny Sokolow, Co-CEO, presented at Noble’s Virtual Equity conference June 4 & 5th. Mr. Sokolow discussed the company’s innovative technology, commercial partnerships, and its quest for mandatory standardization with the NEC, among other topics. A rebroadcast is available here.

Mandatory standardization efforts getting a boost. Management remains optimistic about its push for mandatory standardization, citing recent backing from a prominent government safety leader. The company’s “Code Team” expects further support from key safety organizations to advance its ceiling receptacle technology as a regulatory standard.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

GeoVax Labs (GOVX) – EMA Allows GEO-MVA To Leapfrog To Phase 3 Trial In EU

Posted on by slightbourne@noblecapitalmarkets.com


Tuesday, June 17, 2025

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

GEO-MVA Gets An Accelerated Pathway To European Approval. GeoVax announced that it has received guidance from the EMA (European Medicines Agency) that provides an accelerated path to approval for GEO-MVA, its modified vaccinia ankara (MVA) based vaccine for smallpox/Mpox. It will only be required to conduct immune-bridging and toxicity studies before moving directly to Phase 3. This cuts several years from development time and saves many millions of dollars in clinical expenses.

Only Phase 3 Will Be Needed. The Committee for Medicinal Products for Human Use (CHMP) of the EMA stated that only requirements before beginning a Phase 3 study will be a non-clinical immuno-bridging and toxicity studies. No Phase 1 or Phase 2 studies are required. An MAA regulatory application can be submitted after a single, Phase 3 immuno-bridging study against the approved MVA vaccine (Imvanex or Jynneos, from Bavarian Nordic). The proposed endpoints of the study would be demonstration of immunogenicity to show non-inferiority.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

The GEO Group (GEO) – New USMS Transportation Contract

Posted on by slightbourne@noblecapitalmarkets.com


Tuesday, June 17, 2025

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 103 facilities totaling approximately 83,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 18,000 employees.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

USMS Contract. The GEO Group, through its GEO Transport subsidiary, has entered into a new 5-year contract, including option periods, with the U.S. Marshals Service (USMS) for the provision of secure transportation and contract detention officer services across three service regions covering 26 federal judicial districts and spanning 14 states. The new contract highlights the Company’s diversified service platform, in our view, which provides the Company with numerous growth avenues.

Impact. The new contract is expected to generate up to approximately $147 million over the five-year period, or up to approximately $29 million in annualized revenues per full-year of operations, with margins consistent with GEO’s Managed-Only services contracts, which average approximately 15%.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Kratos Defense & Security (KTOS) – New Award and Expansion; Raising PT

Posted on by slightbourne@noblecapitalmarkets.com


Tuesday, June 17, 2025

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms, and systems for United States National Security related customers, allies, and commercial enterprises. Kratos is changing the way breakthrough technologies for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research, and streamlined development processes. At Kratos, affordability is a technology, and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training and combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.kratosdefense.com.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Award. Kratos was awarded a $25 million task order under the Command and Control System-Consolidated Sustainment and Resiliency contract with the U.S. Space Force Space Systems Command to support ground system capabilities for  Evolved Strategic Satellite Communications (ESS). The ESS system will provide the survivable and endurable satellite communications capability for the Nuclear Command, Control, and Communications mission in all operational environments.

Details. The task order has a 34-month period of performance, which began on  March 14th and will conclude on  November 30, 2027. This was accomplished under the C-SAR single-award indefinite delivery/indefinite quantity (IDIQ) contract awarded to Kratos on  November 15, 2023. The C-SAR IDIQ contract has a maximum value of  $579 million to cover task/delivery orders to support operations, sustainment, enhancements, and constellation capacity.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.